The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Additional provision for US RMBS investigations

26 Jan 2017 07:00

RNS Number : 1779V
Royal Bank of Scotland Group PLC
26 January 2017
 

The Royal Bank of Scotland Group plc

Additional provision for US RMBS investigations and litigation

 

26 January 2017

 

 

The Royal Bank of Scotland Group plc (together with its subsidiaries, "RBS") will announce its Full Year 2016 results on 24 February 2017. Subject to any increase being required by intervening developments, the Q4 2016 results will reflect the taking of a further £3.1bn ($3.8bn) provision in relation to various investigations and litigation matters relating to RBS's issuance and underwriting of US residential mortgage-backed securities ("RMBS"). This takes the total aggregate of such provisions to £6.7bn ($8.3bn) as at 31 December 2016. This further provision would have reduced RBS's Tangible Net Asset Value ("TNAV") per share at 30 September 2016 by 27p to 311p and RBS's Q3 2016 CET1 capital ratio by 135bps to 13.6%. This provision does not directly impact the distributable reserves of The Royal Bank of Scotland Group plc.

 

RBS continues to cooperate with the US Department of Justice ("DOJ") in its civil and criminal investigations of RMBS matters, and RBS considers it appropriate to take this provision now in relation to those investigations as well as other RMBS litigation matters. The duration and outcome of these investigations and other RMBS litigation matters remain uncertain, including in respect of whether settlements for all or any of such matters may be reached.

 

RBS emphasises that further substantial additional provisions and costs may be recognised and, depending on the final outcome, other adverse consequences may occur (see RBS's existing market disclosures). The existing disclosures also provide further details of the US RMBS-related investigations by the DOJ and other agencies and bodies, including several state attorneys general, and various litigation matters.

 

Ross McEwan, RBS's Chief Executive Officer, said:

 

"Putting our legacy litigation issues behind us, including those relating to RMBS, remains a key part of our strategy. It is our priority to seek the best outcome for our shareholders, customers and employees."

 

Ross McEwan (Chief Executive Officer) and Ewen Stevenson (Chief Financial Officer) will host a conference call for investors and analysts at 8.00am UK time today. A replay of the call will be made available shortly afterwards. Only items relating to the above announcement will be discussed on the call; there will be no references and discussion relating to other matters and the Full Year 2016 results. Dial-in details for the call can be found below.

 

Dial-in details:

UK: 0800 694 8082

International: +44 (0) 1452 568 172

US: +1 866 966 8024

Conference ID: 60246489

 

Replay details:

UK FreeCall: 0800 953 1533

Std International: +44 (0)1452 550 000

USA FreeCall: +1 (866) 247 4222

Conference ID: 60246489

 

 

For further information, please contact:

 

Investor Relations

Alexander Holcroft

Head of Equity Investor Relations

+44 (0) 20 7672 1758

 

Matthew Richardson

Head of Fixed Income Investor Relations

+44 (0) 20 7678 1800

 

RBS Media Relations

+44 (0) 131 523 4205

 

Forward Looking Statements

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to RBS and its subsidiaries' regulatory capital position, risk-weighted assets, impairment losses and credit exposures under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements typically containing words such as "intends", "expects", "anticipates", "targets", "plans", "estimates" and words of similar import. These statements concern or may affect future matters, such as RBS's future economic results, business and capital plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that might cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statements. Factors that could cause or contribute to differences in current expectations include, but are not limited to, legislative, fiscal and regulatory developments, competitive conditions, technological developments, exchange rate fluctuations and general economic conditions. These and other factors, risks and uncertainties that may impact any forward-looking statement or RBS's actual results are discussed in RBS's UK Annual Report and materials filed with, or furnished to, the US Securities and Exchange Commission, including, but not limited to, RBS's Reports on Form 6-K and most recent Annual Report on Form 20-F. The forward-looking statements contained in this announcement speak only as of the date of this announcement and RBS does not assume or undertake any obligation or responsibility to update any of the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

Legal Entity Identifier: 2138005O9XJIJN4JPN90

 

ENDS

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQQLBLDFFZBBX
Date   Source Headline
22nd Jul 20202:00 pmRNSChange of Name
16th Jul 20207:00 amRNSIntention to Change Name on 22 July 2020
1st Jul 202012:29 pmRNSDirector/PDMR Shareholding
30th Jun 20204:26 pmRNSTotal Voting Rights
29th Jun 20207:00 amRNSNotice of Redemption
25th Jun 20209:19 amRNSRBSG pricing of US$1.5bn Additional Tier 1 Notes
23rd Jun 20207:00 amRNSChanges to the Alternative Remedies Package
11th Jun 20205:31 pmRNSPublication of Supplementary Prospectus
11th Jun 20208:00 amRNSRBS and NatWest Markets announce appointments
8th Jun 20204:15 pmRNSHolding(s) in Company
8th Jun 20203:38 pmRNSTotal Voting Rights and Capital
8th Jun 20203:20 pmRNSDirector/PDMR Shareholding
29th May 20203:09 pmRNSDirector/PDMR Shareholding
29th May 20202:25 pmRNSTotal Voting Rights
29th May 202012:52 pmRNSDividend Declaration
21st May 202010:15 amRNSAdditional Listing
20th May 20207:04 amRNSRBSG pricing of US$1.6bn of Senior Notes
14th May 20201:00 pmRNSDirector/PDMR Shareholding
13th May 20204:01 pmRNSPublication of Final Terms
12th May 202011:16 amRNSQ1 2020 Pillar 3 Supplement
5th May 20204:57 pmRNSPublication of Supplementary Prospectus
1st May 20204:20 pmRNSPublication of Suppl.Prospcts
1st May 20207:00 amRNSQ1 Interim Management Statement
30th Apr 202012:20 pmRNSTotal Voting Rights
29th Apr 20204:33 pmRNSResult of AGM
29th Apr 20203:01 pmRNSAGM Statement
28th Apr 20203:51 pmRNSDirector/PDMR Shareholding
27th Apr 20204:40 pmRNSSecond Price Monitoring Extn
27th Apr 20204:35 pmRNSPrice Monitoring Extension
27th Apr 20203:58 pmRNSDisclosure of rights attached to equity shares
20th Apr 202012:38 pmRNSDividend Declaration
14th Apr 20204:21 pmRNSVirtual Shareholder Event – 29 April 2020
7th Apr 20204:41 pmRNSSecond Price Monitoring Extn
7th Apr 20204:35 pmRNSPrice Monitoring Extension
6th Apr 20202:14 pmRNSBlock Listing Six Monthly Return
3rd Apr 20204:11 pmRNSAmendment of Final Terms
3rd Apr 20203:24 pmRNSNotice of AGM
2nd Apr 202012:11 pmRNSDirector/PDMR Shareholding
1st Apr 20204:41 pmRNSSecond Price Monitoring Extn
1st Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 202011:34 amRNSRoyal Bank of Scotland Group
1st Apr 20207:00 amRNSResponse to Covid-19
26th Mar 20204:42 pmRNSSecond Price Monitoring Extn
26th Mar 20204:37 pmRNSPrice Monitoring Extension
25th Mar 20204:41 pmRNSSecond Price Monitoring Extn
25th Mar 20204:35 pmRNSPrice Monitoring Extension
24th Mar 20204:42 pmRNSSecond Price Monitoring Extn
24th Mar 20204:38 pmRNSPrice Monitoring Extension
20th Mar 202010:20 amRNSSecond Price Monitoring Extn
20th Mar 202010:16 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.